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Abstract
Salivary duct carcinoma (SDC) is a rare and aggressive malignancy with a high mortality and poor response to treatment in
the advanced setting. Human epidermal growth factor 2 (HER2) can be amplified in a fraction of SDC. We describe the case
of HER2+metastatic SDC of the submandibular gland in a young pregnant woman treated by multimodal treatment
(chemotherapy, radiotherapy and targeted therapy). During pregnancy, a 27-year-old woman developed SDC of the left
submandibular gland with lung and bone metastases. Given the HER2 overexpression, she was treated with trastuzumab,
paclitaxel and cisplatin. Since the tumor had arisen during pregnancy, triptorelin was administered after delivery. A
complete remission was observed, and after eight cycles of chemotherapy, radiotherapy was started in association with
trastuzumab and triptorelin. A prolonged disease control and complete visceral remission were observed. Multimodal
therapy based on patient’s tumor characteristics showed good clinical efficacy in the treatment of metastatic SDC.
INTRODUCTION
Salivary duct carcinoma (SDC) is an uncommon neoplasm of
a ductal cell origin, which accounts for 3–9% of all malignant
salivary gland tumors [1]. It occursmost commonly in the parotid
gland inmen aged>50 years [1]. Interestingly, SDC shares signif-
icant morphologic and immunophenotypic overlap with ductal
carcinoma of the breast, including human epidermal growth
factor 2 (HER2) expression in up to 88% of cases [2, 3].
We describe here the case of HER2+ advanced ductal carci-
noma of the submandibular gland in a young pregnant woman.
CASE REPORT
A 27-year-old Caucasian woman at the 28th week of gestation
developed amass on the left submandibular gland. A biopsy was
performed and the pathology report revealed a high-grade carci-
noma.At the 30thweek, the child laborwas inducedand thenew-
born was found to be healthy. Computed tomography (CT) scan
showed an extensivemass of the left submandibular gland along
with synchronous bilateral pulmonary metastases. Magnetic
resonance imaging (MRI) and CT scan of the head showed amass
infiltrating the submandibular gland, multiple regional lymph
nodes and both cervical spine and lung metastases (Fig. 1).
Positron emission tomography (PET) scan demonstrated
fluorodeoxyglucose (FDG)-avidity in the left neck, in bilateral
lungs and in the cervical spine (C1, C2, C3, C4, C6). The cancer
was considered unresectable.
Pathology was reviewed at tertiary referral center for the
treatment of head and neck cancers, and it revealed both
intraductal and invasive components. Immunohistochemical
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Figure 1: CT scan of the head with submandibulary gland tumor, multiple nodes and pulmonary metastases at diagnosis.
Figure 2: At CT scan, evidence of complete remission of submandibulary gland tumor, multiple nodes and pulmonary metastases.
analysis by chromogenic in situ hybridization showed strong
positive (3+) HER2 expression. The tumor was also weakly
androgen receptor (AR) positive (<20% of tumor cells at
immunohistochemistry). Therefore, histopathological review
concluded for HER2+ AR− SDC.
A palliative chemotherapy regimen with cisplatin (75 mg/m2;
day 1; every 21 days), paclitaxel (80 mg/m2; days 1, 8 and 15) and
trastuzumab (8 mg/kg dose-loading and 6 mg/kg maintenance
treatment, every 21 days) was promptly initiated.Moreover, ovar-
ian suppression with monthly triptorelin 3.75 mg was adminis-
tered concomitantly to systemic therapy. The patient completed
a total of eight cycles of chemotherapy. Compliance to treatment
was excellent; the clinical and hematological tolerability was
very good.
Radiological reassessments (CT, MRI and PET scans) obtained
at the third and sixth courses of chemotherapy (December 2012)
showed complete remission of the primary tumor as well as of
all pulmonary and bone metastatic lesions (Fig. 2).
Aftermultidisciplinary discussion, the patientwas then given
intensity-modulated radiotherapy (IMRT) using megavoltage
equipment (6 MV linear accelerator), using a simultaneous
integrated boost approach delivering in 30 fractions 60 Gy to the
primary site and positive lymph nodes, 50 Gy on microscopic
volume and 45 Gy on cervical vertebrae bones. During IMRT,
trastuzumab was continued (weekly regimen). After the conclu-
sion of IMRT,maintenance treatment of trastuzumab was given.
The treatment was protracted for 9 months; at this point, she
unfortunately developed a voluminous expansive brain lesion in
spite of a persistent complete response at all other secondary
lesion sites. The patient received a local multimodality treat-
ment at Istituto Nazionale Tumori Regina Elena. She underwent
left frontal craniotomy with complete surgical removal of the
central nervous system metastasis confirmed by postoperative
MRI. The patient refused adjuvant stereotactic radiotherapy. At
a subsequent follow-up MRI, on April 2015, a brain relapse was
detected. At this time, the patient underwent stereotactic ther-
apy, delivering 32 Gy in 19 fractions.
In the meantime, the treatment of triptorelin was continued
uninterruptedly until the date of death of the patient due to
brain and liver progression, occurred 36 months after the diag-
nosis, while the other sites (lung and bones) remained stable.
DISCUSSION
SDC is a malignant salivary neoplasm with a poor prognosis.
Due to its rarity and highly aggressive behavior, all cases of SDC
should be discussed within a multidisciplinary team in order to
provide a tailored approach.
Chemotherapy as a single treatment modality is currently
considered for disseminated disease.
In the present case, given the young age of the patient, we
decided to administer upfront treatment with platinum-based
chemotherapy [4].
It is widely accepted that SDC shows remarkablemorphologic
and biologic resemblance to high-grade mammary ductal
carcinoma [5]. Given the marked HER2 expression shown by
the tumor, we decided to treat the patient with trastuzumab,
currently indicated for HER2-amplified breast cancer [6].
Moreover, the efficacy of trastuzumab concomitant to taxane-
containing regimens had already been demonstrated in breast
cancer patients [7]. This prompted us to prescribe a combination
of cisplatin, paclitaxel and trastuzumab; this combination led to
the disappearance of all visible disease. Based on this excellent
result, treatment with trastuzumab was continued.
In breast cancer, endocrine therapy is used in hormone
receptor-positive disease. In this setting, gonadotropin-releasing
hormone agonists (GnRH) inhibit cancer proliferation and
may confer a survival benefit in premenopausal patients [8].
Even though our case did not overexpress hormone receptors
(estrogen and progesterone), we decided to associate triptorelin
in combination with anti-HER2-based systemic therapy. The
decision to administer triptorelin was taken upon the fact
that, in spite of the weak AR expression of our case (<20%),
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the manipulation of GnRH-R signaling by analogues such as
triptorelin has an important role in AR+ SDC, as revealed
by phase II studies [9]. This is even more appropriate if
we consider a hormone-sensitive adenocarcinoma appearing
during pregnancy, when hormonal changes are dramatically
accentuated.
Last, the patient received radiotherapy, in line with the
observation [10] that patients with a partial or complete
clinical response to chemotherapy may be benefit from further
cytoreduction.
Safety and efficacy of high-dose radiotherapy combined with
hormonal treatment were observed.
At the time of encephalic progression, aggressive local ther-
apy might be considered in patient with oligoprogressive dis-
ease. Resection and stereotactic radiotherapy are both reason-
able options to pursue local control with minimal morbidity.
Although of anecdotal nature, the present case supports
consideration for aggressivemultimodal therapeutic approaches
in selected patients affected by metastatic SDC. In partic-
ular, the combination of traditional treatment modalities
(chemotherapy) with further different approaches (targeted
therapy, hormone therapy and radiotherapy) has determined
a complete response and has improved the quality of life of
the patient. Complete remission allowed local analgesia and
the absence of cranial nerve deficiencies for the duration of her
illness.
To this end, selection of the initial therapy should be
guided by both immunohistochemical and androgen receptor
expression of the tumor and by patient performance status.
For patients responding to systemic treatment, consolidation
with radiotherapy seems justified. Interestingly, the disease
remained controlled at the treated sites (lung and neck), while
progressed at brain and liver. Even though brain is usually seen
as a ‘sanctuary’ for drugs [11], it was also demonstrated that
the blood–brain barrier can be altered by brain metastases,
especially from HER-positive cancers [12]. In this setting, the
ability to cross the blood–brain barrier was described for both
bicalutamide [13] and trastuzumab [14].
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